We’re bringing clinical research directly to patients.
Today’s patients are evolving. So, why are we still demanding they conform to the traditional way of participating in clinical trials?
At PRA, we’re elevating clinical trial design to work for patients in today’s modern world. By leveraging our data, expertise, and technologies, we can meet patients exactly where they’re at. From wearables and eConsent to virtual visits and videotelephony, we’re helping bring medicines and treatment to patients faster and more cost-effectively than ever before.
In a recent survey by the Clinical Trials Transformation Initiative (CTTI), 76% of respondents reported preferring a mobile trial scenario over a traditional scenario.
Eliminating the barriers of clinical trial participation.
Today, we’re collecting raw patient data in real-time. With wearable devices like activity trackers and sensors, patients can participate in a trial from the comfort and convenience of their own home. We’re able to monitor vital signs such as heart rate, respiratory data, exercise, and movement levels as patients go about their day-to-day lives, often eliminating the need for excessive site visits and reducing the overall burden on patients.
95% of CTTI respondents were willing to use wearable health monitors.
Wearables provide deep insight into how a drug or treatment affects people in the real world. By leveraging technologies patients are already familiar with, we can improve compliance and patient retention throughout the study. Additionally, real-time data reporting and alerts allow study staff to identify potential risks or challenges early on and rapidly intervene as needed.Learn how wearables are helping improve patient outcomes
Making clinical research a viable care option.
We believe our industry should work for the patients it serves—and we’re committed to making clinical research a viable care option for all patients. Our decentralized, mobile/virtual platform eliminates many of the barriers to entry that patients encounter with clinical research, including geography, time constraints, and monetary investment.
CTTI survey respondents preferred the greater convenience of mobile trials, as well as the elimination of travel to in-person visits.
By utilizing PRA’s mobile clinical trial platform, and our smart wearable technology, we can design studies that pair the right level of technology with your unique needs. To do this, we can recommend an approach to solve the unique challenges of studies.
- The site-based approach that uses remote technologies to collect data between clinic visits.
- The hybrid approach that incorporates virtual visits and home healthcare providers in place of some site visits.
- The fully virtual study that eliminates sites completely.
No matter your needs, we have the expertise and technology to help you develop drugs faster, cheaper, and in a more patient-centric way.Read about PRA’s role in the first fully virtual trial
Embracing a Risk-based Approach
A Phase III, open label, randomized, controlled, multicenter study to assess the safety and efficacy of the Study Drug monotherapy versus the…
PRA’s Unique Model Leads to Client Satisfaction
A randomized, multi-center, double-blind study to compare the efficacy and safety of Study Drug A and Study Drug B as monotherapy in newly diagnosed…
Succeeding with a Risk-Based Approach
A Phase III double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of Drug A in patients with moderate to severe…